Chairman Jing Yue's keynote event at the 2022 Resilient Cities Development and Technology Emergency Symposium

New concept boosts technology empowerment, new model builds security barrier

Chairman Jing Yue's keynote event at the 2022 Resilient Cities Development and Science and Technology Emergency Response Seminar

      On August 21, 2022 Seminar on Resilient Urban Development and Science and Technology Emergency Response was held in Shenzhen Talent Training Institute, hosted by Innovation and Entrepreneurship Institute of Southern University of Science and Technology and Institute of Risk Analysis, Prediction and Control, organized by Jiangxi Institute of Biological Products and guided by China Earthquake Emergency Search and Rescue Center of Ministry of Emergency Management and Shenzhen Emergency Bureau.

      With the theme of "Technology Empowerment, Safety Development", the seminar was attended by 4 academicians and more than 50 famous professors, experts and scholars, mainly focusing on new concepts of urban risk prevention and control, new modes of grassroots social governance, new equipment in the field of disaster relief and rescue, and new technologies in the emergency management industry. As one of the organizers, the leadership of the company attaches great importance to this conference, and the chairman of the board, Ms. Jing Yue, attended the whole conference and gave a speech at the conference, fully demonstrating the mission and responsibility of the company as a high-tech enterprise providing biological immune emergency drugs for the prevention and treatment of dangerous diseases, contributing valuable ideas and insights to promote biomedical science and technology innovation in enhancing urban biosafety and establishing an efficient disposal system for major emergencies. and insights.

(Jing Dong delivered a speech)

      At the meeting, Ms. Jing Yue, the president of the company, delivered a speech on the theme of building a "rapid drug response platform for the treatment of major infectious diseases" (hereinafter referred to as the rapid drug response platform), proposing that the company will take the rapid drug response platform as the core and build "two libraries and one platform The company will build "two libraries and one platform" with the rapid drug response platform as the core. In other words, on the basis of the rapid drug response platform, the company will build a major infectious disease research institute and a standard sample library of antigens and antibodies to form an integrated arsenal for the prevention, treatment and diagnosis of infectious diseases or outbreak of infectious diseases, and establish an integrated platform for "production, medical research and application".

      From the aspect that biosafety is an important part of a safe and resilient city and an important evaluation index of a safe and resilient city, Mr. Jing elaborated that the most important aspect of biosafety is to ensure the safety of people's lives, so to build a safe and resilient city, it is of great practical significance to construct a "rapid drug response platform for the treatment of major infectious diseases". It is of great practical significance to build a safe and resilient city and to construct a "rapid drug response platform for treating major infectious diseases".

(Jing Dong introduced platform ideas in detail)

      For the platform construction ideas Jing Dong introduced: the company will integrate a number of technical advantages to start the construction of the rapid drug response platform, will be horse anti-serum "polyclonal antibodies" as the technical core, through the collection of different pathogens for analysis and research, the development of rapid emergency treatment drugs, and the formation of a comprehensive drug emergency security system. It is hoped that the rapid drug response platform will enable JSI to develop efficient, broad-spectrum, economical and high-quality drugs in the face of diseases that endanger people's health and safety but for which no specific drugs are available, so as to solve the problem of lack of specific treatments for such diseases in clinical settings and provide the general public and the global population with effective, affordable and affordable drugs for special treatment. At the same time, we hope to promote regional biosafety and help the construction of resilient cities under the role of the platform.

      Finally, Mr. Jing also gave a detailed introduction to the experts on the technical advantages of the platform, its composition and functional positioning, and future development planning, and had an in-depth communication and discussion with them on some issues of the platform construction. The experts at the meeting fully affirmed the importance of the rapid drug response platform in building a biosafety barrier to protect human health. As a company with a history of more than 50 years and the courage to assume social responsibility, the company will continue to actively promote the construction of the rapid drug response platform in order to achieve the early launch of the platform and contribute to biosafety and build a resilient city!